SPOTLIGHT: Big Pharma spurns Biogen Idec


Big Pharma just wasn't big enough to swallow Biogen Idec. A slew of drug makers kicked tires at the biotech company, but eventually concluded that the price was too high; after getting no definitive offers, Biogen took itself off the market. Release

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.